Ceperognastat

• Description:

  Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease[1][2].

• Product Name Alternative:

  LY3372689

• UNSPSC:

  12352005

• Target:

  OGA; Tau Protein

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ly3372689.html

• Concentration:

  10mM

• Purity:

  99.09

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  CC(NC1=NC(F)=C(S1)CN2[C@H](C[C@H](CC2)OCC3=NOC(C)=N3)C)=O

• Molecular Formula:

  C16H22FN5O3S

• Molecular Weight:

  383.44

• References & Citations:

  [1]Sergey Shcherbinin, et al. Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia. 07 December 2020 .|[2]Nicolas Jacques Francois Dreyfus, et al. N-[4-fluoro-5-[[ (2s,4s) -2-methyl-4-[ (5-methyl-1,2,4-oxadiazol-3-yl) methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor. Patent WO2018140299A1.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  2241514-56-5